Details of the Drug Reposition

General Information of This Drug (ID: DMEYR4K)

Drug Name
BMS-906024   DMEYR4K
Synonyms
1401066-79-2; UNII-DRL23N424R; BMS 906024; DRL23N424R; (2R,3S)-N1-((S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide; SCHEMBL12543868; DTXSID30161234; CHEBI:131164; ZINC100285156; SB16893; DB12006; KB-145938; Z-3229; BMS-906024, > Butanediamide, N1-((3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluorophenyl)-, (2R,3S)-
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Breast cancer DIS7DPX1 2C60-2C65 Phase 2 [1]
------------------------------------------------------------------------------------
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Lymphoma DISN6V4S 2A80-2A86 Phase 1 [2]
T-cell acute lymphocytic leukaemia DIS7O0DJ 2B33.4 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03691207) A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT01292655) Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health.